Three way takeover battle- Teva: We can close Mylan deal in 2015

Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.

Teva CFO Eyal-Desheh

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) CFO Eyal Desheh remains upbeat about Teva’s attempts to buy Mylan N.V. (Nasdaq: MYL). At the same time, Mylan continues to oppose the takeover bid and believes that it is about to receive US Food and Drug Administration (FDA) approval to market a generic version of Copaxone, Teva’s flagship branded drug for treating multiple sclerosis.

Mylan CEO Heather Bresch and CFO John Sheehan took part yesterday in the Bank of America Merrill Lynch Health Care Conference and analyst Suman Kulkarni published presentations of Mylan and Teva afterwards. On Mylan he wrote, “On generic Copaxone, MYL stated that it went through the FDA’s response to TEVA’s eight citizen petitions and believes that its generic Copaxone meets all the criteria from a scientific perspective. MYL continues to expect approval at any time.”… [READ MORE]

GLOBES logo-eng (1)Published by Globes [online], Israel business news –

Read more about: , , , , , , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems